This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

HAROLD LAUFMAN, Ph.D., M.D.; H. DAVID ROACH, M.D.

AMA Arch Surg. 1953;66(4):552-561.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE FIBRINOLYTIC properties of trypsin have been known for some time. Recently, Innerfield and his associates¹ reported that under certain conditions of administration and dosage the enzyme could be given intravenously to animals and to patients without untoward effects. These workers stated that the intravenous administration of trypsin caused the dissolution of thrombi and also caused a remarkable subsidence of a variety of acute inflammatory conditions. For many years investigators interested in the the thrombosis problem have sought a nontoxic in vivo thrombolytic agent. Therefore the claims of Innerfield's group warrant serious investigation.

We wish to report our clinical experiences with 30 cases of acute and chronic peripheral thrombotic disease and to summarize some preliminary data from our animal studies.

CLINICAL EXPERIENCES

Dose.

—Innerfield and his group recommended a dose of 100,000 to 250,000 units of crystalline trypsin² diluted in 250 cc. of saline once or twice a . . . [Full Text PDF of this Article]

Author Affiliations
CHICAGO

From the Department of Surgery, Northwestern University Medical School.

Footnotes
Read at the Sixtieth Annual Meeting of the Western Surgical Association, Houston, Texas, Dec. 5, 1952.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?